Cell & gene therapy and... reports!

Healthcare through a Kentucky lens. Yeah, it's niche. But neat!

Author

Andrew Steen
October 21, 2025

Not sayin’ I got a NYC-based aging & caregiving startup plugged into the Louisville aging care ecosystem, but hinting at it strongly whilst typing.

🂡

Cell & Gene Therapy

I read this cell & gene therapy piece from Primary Venture Partners last week. It talks about infrastructure, including logistics. Given the role of logistics in cell & gene therapy and UPS Worldport in town, I once thought this could be a thing for Louisville. Maybe still. Maybe. [See Philly.]

The Cell & Gene Therapy Frontier: The Next System Build-Out in Healthcare

For more than a century, modern medicine has been defined by how effectively we manage disease – by controlling symptoms, slowing progression, and extending longevity. Cell and gene therapy (CGT) breaks that paradigm: treatments designed not to manage illness, but to eliminate its biological cause e

www.linkedin.com/pulse/cell-gene-therapy-frontier-next-system-build-out-osx7c

Chris Otts wrote this in December 2023.

Biotech company hopes to make Louisville a hub for cell therapy

The former Talaris space on the U of L Health Sciences Campus downtown won't be quiet for long.

www.wdrb.com/news/business/biotech-company-hopes-to-make-louisville-a-hub-for-cell-therapy/article_e857e65a-9918-11ee-a5bc-57ef373ca4ff.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share

🤷‍♂️ 

ICYMI, our conversation with Paducah Tilghman alum and Gene and Cell Therapy Diligence Expert Emily Walsh Martin, PhD.

Health Distilled with Emily Walsh Martin

“So the first decade of my career in biopharma was really in small molecules and proteins and antibodies. And then the second decade, starting at Shire, was in cell and gene therapy.”

www.liverpoollane.com/podcast/health-distilled-with-emily-walsh-martin

Cleveland Clinic ⇄ Khosla Ventures

“Khosla Ventures and Cleveland Clinic signed a deal in which the health system will test new technologies that span AI, digital health and next-generation therapeutics from the VC firm’s portfolio companies—and the two will explore opportunities to incubate new companies together,” Forbes reported.

Cleveland Clinic and Khosla Ventures Announce Strategic Collaboration

The new relationship combines the organizations’ unique strengths, aiming to reimagine healthcare delivery and create solutions that address some of the most pressing challenges in the field.

newsroom.clevelandclinic.org/2025/10/14/cleveland-clinic-and-khosla-ventures-announce-strategic-collaboration?_bhlid=580af28fe3eed96e1c1fa54c431e8e1d2f1ef574

“[Bruce Booth has] ‘killed’ a bunch of seed-stage startups for the failure to replicate the ‘transformational finding’ of an academic lab.” Word.

Twenty Years In Early Stage Biotech VC (Part 1): Science - LifeSciVC

In the blink of an eye, twenty years have passed: in mid-October 2005, I joined Atlas Venture as a principal on the global life science team.  We closed Fund VII a few months after I joined; and, just a few

lifescivc.com/2025/10/twenty-years-in-early-stage-biotech-vc-part-1

SVB’s The Future of Healthtech 2025

Another new report with a ton of interesting data. Two slides of note.

Most Active Healthtech Investors. Honestly, I didn’t do the research. But, LRVHealth was in RxLightning’s Series A. Other than that—Kentucky?

“Starting in 2023, however, provider operations — tools for revenue cycle management, patient outreach, scheduling, analytics and other front or back office tasks — has taken the plurality of cash.” The good news is, those are areas where the Commonwealth could compete.

P.S. : HLTH is going on in Vegas this week. I’m not there. But, stay tuned.

P.S.S. : I was today year’s old when I discovered Rick Springfield’s real name is Richard Springthorpe. You’re welcome.

SHARE!

SHOW UP!